The race to patent psychoactives

Patenting cannabinoids is an established practice in life sciences, but there are a host of other controlled substances in the field of psychoactives that companies have been rushing to patent.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Plant Varieties

Overcoming the challenges of US patent eligibility for nature-based elements

26 March 2024 Applicants face tough scrutiny for claims around the laws of nature, but details of new processes, steps or guidance can help patents pass the courts’ two-step test, says Michael Taylor of Harness IP.

Plant Varieties

Plant variety rights: UK holders must act

27 April 2023 An important post-Brexit deadline for UK holders of Retained EU Plant Variety Rights is approaching, explain Alice Smart and Simon Bradbury of Appleyard Lees.

Plant Varieties

Rival sues Monsanto, Bayer over GM plant tech

11 August 2022 Firms accused of using GM tech for herbicide-resistant plants | Plaintiff says its patented tech helps farmers to innovate | US District Court for the District of Delaware.

More features

Mental health in IP: ‘We have a clear picture of the problem’

From Edwards to Insulet: Three key medical device cases of 2025

Edwards v Meril: Behind the UPC’s landmark medtech showdown

5 ways the USPTO director is changing US innovation

EU unveils sweeping pharma, biotech, and medical device reforms

Mirum targets generics in quartet of suits over liver treatment

Hogan Lovells and Cadwalader strike historic deal to create $3.6bn firm

Edwards v Meril: 3 insights from the UPC Court of Appeal’s decision

The race to patent psychoactives

More on this story

Editor's picks

Editor's picks

More features